Board to consider Interim Dividend
Suven Life Sciences Ltd has informed BSE that a Board Meeting of the Company will be held on January 30, 2018, inter alia, to consider and take on record the following matter(s):1. To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended December 31, 2017.2. To consider declaration of Interim Dividend, if any, for the financial year 2017-18 and related matters etc. and... Board to consider Dividend
Please note that a Board Meeting of our Company will be held on Tuesday, the 30th January, 2018 at 10:30 a.m. at the Registered Office, SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and take on record the following matter(s): 1) To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2017... Closure of Trading Window
To consider, inter alia, and take on record the following matter(s): 1) To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2017 2) To consider declaration of Interim Dividend, if any, for the financial year 2017-18 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to... Suven gets product patents in China, Sri Lanka
Suven Life Sciences has secured a product patent each from China and Sri Lanka corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative... Press Release / Media Release
Suven Life Sciences secures Product Patents in China and Sri Lanka Statement Of Investor Complaints/Grievances, For The Quarter Ended 31St December, 2017
Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, please find below the statement of Investor complaints/grievances, for the quarter ended 31st December, 2017. Shareholding for the Period Ended December 31, 2017
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Suven gets product patents from Canada, India for neurodegenerative disorder treatment
Suven Life Sciences has secured a product patent each from Canada and India for the treatment of neurodegenerative disorders. These patents are valid through 2034 and 2028, respectively, the company... Press Release / Media Release
Suven Life Sciences secures Product Patents in Canada and India Suven gets product patent for cognitive disorders
Suven Life Sciences has secured a product patent each from India and the US for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2029 and 2033...